ClinicalTrials.gg
Active, not recruitingNCT05058040Updated Jan 24, 2025

A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

A Phase 4 interventional study of Sodium Oligomannate Capsules in Alzheimer Disease, sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd.. Active, not recruiting at 63 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,500
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Enrollment
2nd of 176
2,500 · median 100
Started
2021
with 15 others
Phase 4
11 of 260
4 open now
Primary completion
2025-01
later than 10 of 161 live
Registered
72nd of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 2nd largest by enrollment of the 176 interventional ones that give a count, is one of 16 that started in 2021, is one of 11 in phase 4, reaches primary completion later than 10 of the 161 other live ones, and was the 72nd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

A clinical study to evaluate the long-term safety of Sodium Oligomannate Capsules (GV-971)

Read the detailed description

Sodium oligomannate (Code: GV-971), a marine-derived oligosaccharide after extraction, separation and degradation from algae, can play a role in the treatment of Alzheimer's disease by reconditioning the dysbiosis of gut microbiota, preventing peripheral immune cells from invading the brain, inhibiting the inflammatory response in the brain, and targeting protein folding errors in the brain tissue. Phase I clinical study shows GV-971 was safe and tolerated in healthy adult volunteers when administered continuously at 1200 mg/dose or 1500 mg/day (750 mg/dose, bid) for 5 days. Phase II and III clinical studies show that the treatment of GV-971 at 900 mg/day dosage for 36 weeks can significantly improve the cognitive function of patients with mild to moderate Alzheimer's disease (AD) and was safe and well-tolerated.

Sodium Oligomannate Capsules obtained approval from China's National Medical Products Administration (NMPA) on November 2, 2019, with approval letter number of 2019S00571. This product is a chemical drug with a registration classification of 1.2. It is approved for the clinical indication of mild to moderate Alzheimer's disease and the function of improving the cognitive function of patients. The clinical dosage and administration is 3 capsules (450 mg)/time, bid, po.

Due to the limited number of subjects and observation period of medication in completed GV-971 clinical studies, and the screening of patients with the strict inclusion and exclusion criteria, the adverse reactions and long-term safety of GV-971 cannot be comprehensively observed and recorded. Therefore, according to the requirements of the NMPA for the marketing of new drugs, this study is intended to further carry out a post-marketing investigation on expanded population using a design of a 96-week intensive monitoring clinical trial to determine the incidence of known adverse reactions of GV-971 under long-term administration, observe the occurrence of new adverse reactions, analyze the correlation, incidence, severity, and risk factors of adverse reactions/events, and better guide the rational use of drugs in clinical practice.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects eligible for this study must meet all of the following criteria:

    1. ≥18 years of age;
    2. Signed form;
    3. Patients receiving GV-971 treatment prescribed by clinicians;

Exclusion criteria

Exclusion Criteria:

  • A subject may be excluded from participation in the study if any of the following apply:

    1. Patients who may be allergic to Sodium Oligomannate Capsules as judged by the investigator;
    2. Female participants who are pregnant or lactating;
    3. Patients who cannot cooperate to complete the follow-up inquiries;
    4. Any other diseases or conditions that are inappropriate to participate in this clinical trial in the opinion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,500 participants (actual)

Study arms

  • Experimental
    GV-971

    The recommended dose regimen for subjects: GV-971 450 mg (3 capsules) per dose, bid, po. in morning and evening

    Drug: Sodium Oligomannate Capsules

Interventions

  • Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.

06

What researchers measure

Primary outcomes

  1. Long-term safety of GV-971 in clinical practice during 48 weeks

    The incidence of adverse reactions and AE/SAE in patients treated with GV-971 during the 48-week monitoring period

    Time frame: Week 48

  2. Long-term safety of GV-971 in clinical practice during 96 weeks

    The incidence of adverse reactions and AE/SAE in patients treated with GV-971 during the 96-week monitoring period

    Time frame: Week 96

Secondary outcomes

  1. Safety Endpoints: Vital signs, laboratory tests , electrocardiogram, and early withdrawal from the study during 48 weeks

    The incidence of adverse events and adverse reactions in patients with liver insufficiency and renal insufficiency receiving GV-971 during 48 weeks

    Time frame: 48-week

  2. Safety Endpoints: Vital signs, laboratory tests , electrocardiogram, and early withdrawal from the study during 96 weeks

    The incidence of adverse events and adverse reactions in patients with liver insufficiency and renal insufficiency receiving GV-971 during 96 weeks

    Time frame: 96-week

07

Study locations

63 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jan 2025, 43 months after the start.

Of 41 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 43 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2021
First posted
Sep 27, 2021
StartActual
Jun 2, 2021
Primary completionEst.
Jan 2025
CompletionEst.
Apr 2025
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05058040
Lead sponsor
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Sep 27, 2021
Start date
Jun 2, 2021
Primary completion
Jan 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Jan 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GV-971

Start the discussion